Drugs / ClotFoam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02264730 | Jul 2014 → Jan 2015 | hemorrhagic disease | Biomedica Management Corporation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ClotFoam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02264730 ↗ |
| Modality | Other / unclassified | “ClotFoam® is an investigational product-a gelatin-based hydrogel carrying a fibrin monomer” NCT02264730 ↗ |
| Route | Topical | “All subjects who meet eligibility criteria and who provide informed consent to participate will be assigned to ClotFoam topical treatment.” NCT02264730 ↗ |